ESMO Preceptorship on Breast Cancer, 26-27 July 2024, Munich, Germany
Online application is now open until 28 May 2024
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Access the most recent science of the year in breast cancer, wherever you are
Keep up to date with the latest, practice-changing publications and join the discussion with key opinion leaders
How to apply the latest, best practice recommendations to your daily practice? Join this live discussion and get your questions answered by the ESMO Guidelines experts
Empower yourself with knowledge, inspiration, and tools to make a difference in gynaecologic oncology.
Submit your research for MAP 2024 by 23 July 2024. Don't miss this opportunity to contribute to cutting-edge discussions in precision oncology.
Online application is now open until 28 May 2024
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
No difference in risk recurrence or pregnancy outcomes was reported between young women with BRCA1 or BRCA2 mutations conceiving naturally and those using fertility treatments
In the TROPION-Breast01 trial, adverse events of special interest were generally low grade, easily managed and did not compromise scheduled treatment
In her key lecture, the 2024 ESMO Breast Cancer Awardee Prof. Hope S. Rugo reflects on the current challenges in the field
However, a higher objective response rate with atezolizumab was reported in the IMpassion132 trial suggesting that at least some patients could benefit from it
Individualised assessment of initial response to therapy may pave the way for chemotherapy-sparing treatment, but it requires that multidisciplinary teams adapt their current practices
The rapidly increasing integration of AI into many aspects of breast cancer management calls for urgent definition of expected levels of evidence and bespoke regulatory and reimbursement processes
While novel agents continue to enrich the therapeutic armamentarium in this setting, patients ask for a longer survival, but also for a better quality of life
A study reports a disease-free survival benefit with six years of maintenance therapy with imatinib compared to the 3-year standard of care
A benefit was observed in women with germline BRCA1/2 mutations when treated with the PARP inhibitor alone or in combination with apatinib
No difference in risk recurrence or pregnancy outcomes was reported between young women with BRCA1 or BRCA2 mutations conceiving naturally and those using fertility treatments
In the TROPION-Breast01 trial, adverse events of special interest were generally low grade, easily managed and did not compromise scheduled treatment
In her key lecture, the 2024 ESMO Breast Cancer Awardee Prof. Hope S. Rugo reflects on the current challenges in the field
Primary results from the DESTINY-PanTumor01 study
First global study in young women with high-risk genes and a pregnancy after breast cancer shows Assisted Reproductive Techniques (ART) are safe, with no increase in breast cancer recurrence
However, a higher objective response rate with atezolizumab was reported in the IMpassion132 trial suggesting that at least some patients could benefit from it
Optimal cancer care for all must be prioritised to secure the delivery of the UN’s sustainable development goals
Individualised assessment of initial response to therapy may pave the way for chemotherapy-sparing treatment, but it requires that multidisciplinary teams adapt their current practices
The rapidly increasing integration of AI into many aspects of breast cancer management calls for urgent definition of expected levels of evidence and bespoke regulatory and reimbursement processes
Primary results from the DESTINY-PanTumor01 study
Approval is based on pharmacokinetic, dosimetry, and safety data from NETTER-P study in adolescent patients and also on the extrapolation of efficacy outcomes observed in NETTER-1 study which supported the original approval in adult patients
Findings from the TRIANGLE study
It is intended for the treatment of patients with previously treated metastatic colorectal cancer
Findings from the NEOpredict-Lung study
The innovaTV 301 study results fulfill the post-marketing requirement of the previous accelerated approval
Frequent occurrence of NECTIN4 amplifications in other cancer types is promising for development of NECTIN4-targeted antibody drug conjugates in a tumour-agnostic context
Findings from the phase I TROPION-PanTumor01 study
New indication concerns combination therapy with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations
First global study in young women with high-risk genes and a pregnancy after breast cancer shows Assisted Reproductive Techniques (ART) are safe, with no increase in breast cancer recurrence
ESMO Breast Cancer 2024 will be held in Berlin, Germany, between 15-17 May where the latest research in breast cancer will be presented
The European Lung Cancer Congress 2024 is the annual appointment that brings together various experts in the field of thoracic oncology
The ESMO Sarcoma and Rare Cancers Congress 2024 will be held in Lugano from 14 to 16 March and will bring together world-renowned experts among researchers and practitioners, to present and discuss the latest advances in the treatment and care of sarcoma and rare cancers in general
The ESMO Targeted Anticancer Therapies Congress 2024 is the annual multi-stakeholder meeting that focuses on the development of novel anticancer therapies and how this can transform the current knowledge and impact clinical care
Experts predict death rates from all cancers for the EU and UK for 2024
The ESMO Immuno-Oncology Congress 2023, where experts discuss the latest scientific developments in this fast-moving field of cancer treatment, will be held in Geneva, Switzerland, between 6-8 December, also with a virtual component
The ESMO Asia Congress 2023 is the annual meeting to present and discuss the latest scientific and clinical advances across the entire field of oncology, of relevance at a global level and specifically for the Asia-Pacific region.
Evidence is building up that strong political action has the potential to tackle two of our era’s biggest challenges: climate change and the increasing burden of cancer on society
Tom Powles, Editor in Chief of ESMO’s flagship journal Annals of Oncology; Solange Peters, ESMO Past President; and Fabrice André, President Elect of the Society have been recognised as leading and influential researchers for their remarkable achievements in cancer care
Following the Ombudsman’s recent findings of maladministration regarding the Commission’s interactions with tobacco lobbyists and its subsequent decision not to bring forward the proposed Council recommendation on smoke-free environments, it is beyond belief that the Commission now appears to have removed plans to publish an evaluation – originally meant to come in 2022 - of the Tobacco Products Directive from its implementation
The European Society for Medical Oncology (ESMO) announced today that the 2024 ESMO Breast Cancer Award is conferred to Hope S. Rugo, Professor of Medicine and Winterhof Family Professor of Breast Cancer at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
The European Society for Medical Oncology (ESMO) announced today that the 2024 Heine H. Hansen Award is bestowed to Enriqueta Felip
The nomination process for the 2024 ESMO Society Awards is now open
ESMO is pleased to announce the newly appointed Committee and Working Group Chairs who started their mandates in January 2024
The European Society for Medical Oncology (ESMO) has announced today that the 2024 ESMO TAT Honorary Award is bestowed to Funda Meric-Bernstam
ESMO is pleased to announce the renewal of its status as non-State actor in official relations with the World Health Organization - a privilege granted to non-governmental organisations, which recognises ESMO’s sustained and systematic engagement in the interest of the WHO
An evidence-based and patient-centred approach to close the care gap for a healthier Europe
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.